In the United States, where invasive disease caused by group Y has emerged over the past decade, universal preadolescent immunization programs were implemented with the quadrivalent meningococcal conjugate vaccine [2], find more [18], [19] and [20].

In other countries, such as Canada, universal infant or toddler immunization programs were implemented in all provinces with meningococcal C conjugate vaccine, with some provinces choosing to provide broader meningococcal protection by immunizing all preadolescents with the quadrivalent meningococcal conjugate vaccine [33]. Finally, due to the unique epidemiology of meningococcal disease where, in contrast to Haemophilus influenzae type b and pneumococcal disease, a second peak of incidence occurs later, the need for and timing of a booster vaccination is a topic of active debate [34]. Given the constantly changing epidemiology of invasive meningococcal disease, the availability of a quadrivalent meningococcal vaccine that is immunogenic and well-tolerated in all ages will provide more programmatic flexibility by providing broader coverage to all age groups with a single product. In summary, this study demonstrated that MenACWY-CRM (Menveo®, Novartis Vaccines and Diagnostics), which is currently licensed in the United States, Canada, Australia and Europe for individuals 11–55 years of age, Nintedanib order is immunogenic

and well-tolerated in children 2–10 years of age and compares favorably to MCV4 (Menactra®, Sanofi Pasteur) that was previously licensed for this age group. With previous studies demonstrating the safety and immunogenicity of MenACWY-CRM in infants and toddlers, a single product may soon be available to provide broad protection against groups A, C, Y and W-135 across the age spectrum

from infancy to 55 years only of age. We are grateful to the children and their families for participating in the study. We thank Gieselle Bautista for reviewing the manuscript and all of the other nurses and staff for their careful attention to detail. We appreciate the contribution of Novartis employees Maggie McCarthy and Charmelle Casella who monitored and supported study conduct, Dr. Annette Karsten who conducted the serology analyses and Drs. Lisa DeTora and Pinki Rajeev who provided support for the manuscript tables and facilitated the manuscript review. We thank Dr. Bruce Smith and Donna MacKinnon-Cameron at the Canadian Center for Vaccinology for their independent evaluation of the statistical analysis plan, report and independent statistical analysis. Conflict of interest statement: L. Bedell, C. Gill and P. Dull are employees of Novartis Vaccines and Diagnostics. The other authors have no financial interest in the vaccine or its manufacturer but received research funding to undertake the study. Funding: The study was funded by Novartis Vaccines and Diagnostics.